Effect of Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid or Gemcitabine vs Observation on Survival in Patients With Resected Periampullary Adenocarcinoma
John P. Neoptolemos(University of Liverpool), Charlotte Rawcliffe(University of Liverpool), Paula Ghaneh(University of Liverpool), Caroline S. Verbeke(Oslo University Hospital), F Lacaine(Sorbonne Université), Daniel H. Palmer(University of Liverpool), Andrew Scarfe(Cancer Institute (WIA)), Markus W. Büchler(Heidelberg University), Attila Oláh(Semmelweis University), Ross Carter(Glasgow Royal Infirmary), Bengt Glimelius(Uppsala University), Richard Charnley(Newcastle upon Tyne Hospitals NHS Foundation Trust), Juan W. Valle(Cancer Research UK Manchester Institute), Fiona Campbell(University of Liverpool), Niall C. Tebbutt(Austin Health), Alan Anthoney(St James's University Hospital), Christopher Halloran(University of Liverpool), Trevor F. Cox(University of Liverpool), David Smith(City Of Hope National Medical Center), Malcolm J. Moore(University Health Network), Markus M. Lerch(Ludwig-Maximilians-Universität München)
Cited by 590
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
|New England Journal of Medicine|2000|3k